Analyst Presentations In Brief
This article was originally published in The Tan Sheet
Executive SummaryChattem "ready to go" on Allegra switch
You may also be interested in...
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.
A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.